Bayer bags iPSC specialist BlueRock Therapeutics
Bayer has widened its pipeline in neurology, cardiology, and immunology by acquiring induced pluripotent stem cell specialist BlueRock Therapeutics.
Liquid biopsy identifies residual breast cancer
Using a platform tailored to patients specific cancer mutations, British and US researchers for the first time detected residual disease in breast cancer patients.
Google maps for tumours and organs
Transgenes licenced oncolytic virus fails in Phase III
SillaJen, the licensor for French immunoncology specialist Transgene SA, has stopped enrolment into the Phase III Phocus trial after an Independent Data Review Comittee predicted the study endpoint won’t be met.
Alizé Pharma 3 bags largest EU financing so far
Venture Captital specialist LSP led a 67m Series A financing in peptide developer Alizé Pharma 3.
Better TNF? receptor blockers on the horizon
Two research teams have unraveled the complex dynamics of TNF? receptor signaling and have identified compounds that may be safer than current treatments.
European Commission approves ten GMOs
The European Commission has authorised ten genetically modified products.
Zambon heading to US market with 500m acquisition
Zambon is set to acquire respiratory company Breath Therapeutics for up to 500m to complement its respiratory pipeline and get access to the US market.
Gut microbiome boosts muscle strength
Swedish researchers have demonstrated that the gut microbiome can significantly affect the proper development and strength of skeletal muscle.
Curetis lower respiratory tract panel ready for FDA clearance
Molecular diagnostics expert Curetis NV has filed for US FDA clearance of Unyvero LRT to speed up diagnosis of patients with lower respiratory tract (LRT) infections.